Releases
VERA
43.12
-1.62%
-0.71
  • All
  • Financials
  • Insiders
More
Webull provides the latest Vera Therapeutics, Inc. (VERA) stock and general news. This information may help you make smarter investment decisions.
About VERA
Vera Therapeutics, Inc. is a late-stage biotechnology company. The Company is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its product candidate, atacicept, is a self-administered fusion protein that blocks both a B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL) which stimulates B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. Atacicept is being developed for the treatment of immunoglobulin A nephropathy (IgAN), a rare autoimmune disease that can lead to dialysis, kidney transplant, serious disease, and early death. The Company is also engaged in developing MAU868, a monoclonal antibody designed to neutralize infection with BK Virus, a polyomavirus that can have devastating consequences in certain settings such as kidney transplants.